• Je něco špatně v tomto záznamu ?

Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer

T. Klatte, E. Xylinas, M. Rieken, LA. Kluth, M. Rouprêt, A. Pycha, H. Fajkovic, C. Seitz, PI. Karakiewicz, Y. Lotan, M. Babjuk, M. de Martino, DS. Scherr, SF. Shariat,

. 2014 ; 191 (5) : 1238-43.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063818

PURPOSE: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. MATERIALS AND METHODS: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. RESULTS: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. CONCLUSIONS: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063818
003      
CZ-PrNML
005      
20140708091420.0
007      
ta
008      
140704s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.juro.2013.11.106 $2 doi
035    __
$a (PubMed)24333243
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klatte, Tobias $u Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
245    10
$a Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer / $c T. Klatte, E. Xylinas, M. Rieken, LA. Kluth, M. Rouprêt, A. Pycha, H. Fajkovic, C. Seitz, PI. Karakiewicz, Y. Lotan, M. Babjuk, M. de Martino, DS. Scherr, SF. Shariat,
520    9_
$a PURPOSE: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. MATERIALS AND METHODS: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. RESULTS: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. CONCLUSIONS: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.
650    12
$a ABO systém krevních skupin $7 D000017
650    _2
$a karcinom z přechodných buněk $x krev $x patologie $7 D002295
650    _2
$a kohortové studie $7 D015331
650    _2
$a progrese nemoci $7 D018450
650    _2
$a lidé $7 D006801
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $x krev $x epidemiologie $7 D009364
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory močového měchýře $x krev $x patologie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Xylinas, Evanguelos $u Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York; Department of Urology, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris Descartes University, Paris, France.
700    1_
$a Rieken, Malte $u Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York.
700    1_
$a Kluth, Luis A $u Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Rouprêt, Morgan $u Department of Urology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancérologie GRC5, University Paris 6, Paris, France; Department of Urology, University Hospital Basel, Basel, Switzerland.
700    1_
$a Pycha, Armin $u Department of Urology, Central Hospital of Bolzano, Bolzano, Italy.
700    1_
$a Fajkovic, Harun $u Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
700    1_
$a Seitz, Christian $u Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada.
700    1_
$a Lotan, Yair $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
700    1_
$a Babjuk, Marko $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a de Martino, Michela $u Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
700    1_
$a Scherr, Douglas S $u Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York.
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York. Electronic address: sfshariat@gmail.com.
773    0_
$w MED00003040 $t The Journal of urology $x 1527-3792 $g Roč. 191, č. 5 (2014), s. 1238-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24333243 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140708091710 $b ABA008
999    __
$a ok $b bmc $g 1031302 $s 862550
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 191 $c 5 $d 1238-43 $i 1527-3792 $m The Journal of urology $n J Urol $x MED00003040
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace